These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24844043)

  • 21. Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions.
    Bao Y; Wen K; Johnson P; Jeng PJ; Meisel ZF; Schackman BR
    Health Aff (Millwood); 2018 Oct; 37(10):1596-1604. PubMed ID: 30273045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of prescription monitoring programs on chronic pain management.
    Wang J; Christo PJ
    Pain Physician; 2009; 12(3):507-15. PubMed ID: 19461820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research.
    Worley J
    Issues Ment Health Nurs; 2012 May; 33(5):319-28. PubMed ID: 22545639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National drug control policy and prescription drug abuse: facts and fallacies.
    Manchikanti L
    Pain Physician; 2007 May; 10(3):399-424. PubMed ID: 17525776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of North Carolina's prescription drug monitoring program on the prescribing behaviors of the state's providers.
    Ringwalt C; Garrettson M; Alexandridis A
    J Prim Prev; 2015 Apr; 36(2):131-7. PubMed ID: 25466768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disclosure of Use and Abuse of Controlled Substances Among Psychiatric Outpatients.
    De Marco Centeno P; Baig M; Lee SE; Lane CJ; Lagomasino IT
    J Psychiatr Pract; 2015 Nov; 21(6):412-8. PubMed ID: 26554323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Government Legislation in Response to the Opioid Epidemic.
    Jones MR; Novitch MB; Sarrafpour S; Ehrhardt KP; Scott BB; Orhurhu V; Viswanath O; Kaye AD; Gill J; Simopoulos TT
    Curr Pain Headache Rep; 2019 May; 23(6):40. PubMed ID: 31044343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances.
    Fass JA; Hardigan PC
    J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery program directors' knowledge of opioid prescribing regulations: a survey study.
    Yorkgitis BK; Raygor D; Bryant E; Brat G; Smink DS; Crandall M
    J Surg Res; 2018 Jul; 227():194-197. PubMed ID: 29804853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How does use of a prescription monitoring program change pharmacy practice?
    Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
    J Am Pharm Assoc (2003); 2013; 53(3):273-81. PubMed ID: 23699676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers.
    Wright RE; Reed N; Carnes N; Kooreman HE
    Pain Physician; 2016 Jan; 19(1):E197-208. PubMed ID: 26752487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Legal bases for the control of analgesic drugs.
    Shapiro RS
    J Pain Symptom Manage; 1994 Apr; 9(3):153-9. PubMed ID: 8014528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. State Legal Restrictions and Prescription-Opioid Use among Disabled Adults.
    Meara E; Horwitz JR; Powell W; McClelland L; Zhou W; O'Malley AJ; Morden NE
    N Engl J Med; 2016 Jul; 375(1):44-53. PubMed ID: 27332619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physician Autonomy and the Opioid Crisis.
    Guevremont N; Barnes M; Haupt CE
    J Law Med Ethics; 2018 Jun; 46(2):203-219. PubMed ID: 30146981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
    Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
    J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of state prescription drug monitoring programs: a state-by-state survey.
    Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prescription Painkiller Epidemic: The Short History of a Rapid Evolution.
    Florine BL
    Northwest Dent; 2017 Jan; 96(1):33-35. PubMed ID: 30549747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.